
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projected to see strong earnings growth, with GAAP earnings anticipated to rise to $4.73 per diluted share for 2025 and $5.17 per diluted share for 2026, reflecting positive adjustments from previous estimates. The Human Nutrition and Health segment is expected to drive sequential revenue growth, supported by improved gross and net margins, which are forecasted to enhance moving forward. Additionally, with a potentially debt-free status by the end of the year, Balchem's robust balance sheet positions the company well for future accretive mergers and acquisitions to further strengthen its market position.
Bears say
Balchem Corporation’s financial outlook is tempered by a forecasted decline in earnings per diluted share for 2026 to $5.10, down from a prior estimate of $5.17, indicating potential revenue stagnation. Furthermore, the company's Human Nutrition and Health division reported fourth-quarter revenue of $166.1 million, slightly below the projected $170 million, and the Animal Nutrition segment also underperformed with sales of $56.4 million compared to the anticipated $60 million. The overall risks to Balchem's performance include slower growth in core businesses, inflationary pressures, and uncertainties surrounding new product launches and regulatory approvals, which contribute to a cautious view of the stock's future viability.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares